- Overview of current management approaches for HER2-positive metastatic breast cancer
- Novel HER2-targeted therapies in breast cancer (eg, trastuzumab deruxtecan, tucatinib, neratinib)
- Clinical impact of TROP2 and TROP2 targeting antibody–drug conjugates
- The emerging role of HER3 in breast cancer and novel anti-HER3 antibody–drug conjugates in development
Mark D. Pegram, MD
Susy Yuan-Huey Hung Professor
Director, Breast Cancer Program
Associate Director for Clinical Research
Associate Dean for Clinical Research Quality
Stanford Cancer Institute
Stanford University, School of Medicine
The goal of this activity is to improve the knowledge, competence, and performance of learners to utilize diagnostics to guide treatment of various HER2-, HER3-, and TROP2-altered cancers in the metastatic setting, including breast, gastrointestinal, and lung.
This program is intended for oncologists, pathologists, and other healthcare providers who care for patients with breast, gastrointestinal, and lung cancers.
Upon completion of this activity, participants should be able to:
- Review evidence-based guidelines and expert recommendations for assessing HER2, HER3, and TROP2 in the metastatic setting for breast, gastrointestinal, and lung cancers
- Appraise the available clinical data for established and emerging HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers
- Implement best practices for HER2, HER3, and TROP2 diagnostic testing and interpretation to guide integration of the latest targeted therapies into individualized treatment plans
- Identify patients eligible to enroll on important ongoing clinical trials based evaluating novel HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Lifelong Learning (Part II) and Self-Assessment Module (SAM) points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.